Implementation of personalized T-cell therapy in the treatment of pancreatic cancer

VernacularTitle:个体化T细胞疗法在胰腺导管腺癌中的临床探索
Author: Rienk OFFRINGA ¹ ; Zibo MENG ; Hongkun CAI ; Xiaoyan SHI ; Heng MEI ; Heshui WU
Author Information

1. 海德堡大学医院外科诊所胰腺癌研究部门　德国癌症研究中心胃肠道分子肿瘤学部　中德胰腺癌个体化治疗实验室，海德堡　69120
Publication Type:Journal Article
Keywords: Pancreatic neoplasms; Antineoplastic protocols; Cancer immunotherapy; Engineered T-cell therapy; Single cell RNA-sequencing
From: Chinese Journal of Surgery 2025;63(8):666-671
CountryChina
Language:Chinese
Abstract: Pancreatic ductal adenocarcinoma is profoundly treatment-resistant, due to intrinsic properties of the tumor cells and the complex tumor microenvironment. Consequently, surgical resection of the primary tumor is still the only intervention that significantly prolongs patient survival. This points at an urgent need for more effective (neo)adjuvant strategies to increase the fraction of patients eligible to surgery and to counter post-surgery disease recurrence. The advent of single-cell RNA-sequencing has created an opportunity for the development of a highly potent, patient-tailored adjuvant treatment that is based on the infusion of genetically engineered autologous T-cells armed with tumor-reactive T-cell receptors as identified in the patient′s own tumor sample.